POM-V Prescription Required

Coglapix Suspension for Injection for Pigs

Active ingredient: Actinobacillus pleuropneumoniae

Form

Injection

Species

Pigs

Manufacturer

Ceva Sante Animale

VMD MA No.

14966/5063

What it's used for

Onset of immunity: 21 days following second vaccination Duration of immunity: 16 weeks following second vaccination

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Actinobacillus pleuropneumon...

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Coglapix Suspension for Injection for Pigs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Onset of immunity: 21 days following second vaccination
Duration of immunity: 16 weeks following second vaccination

The preferred site of administration is the neck region.
Vaccination schedule: 2 doses administered to animals from 7 weeks of age with an
interval of 3 weeks between doses.
Shake well before use.
Use sterile syringe and needle, respect aseptic conditions of vaccination.

None.

Pigs
Very common
(>1 animal / 10 animals treated):
Injection site swelling
Common
(1 to 10 animals / 100 animals
treated):
Elevated temperature
Uncommon
(1 to 10 animals / 1000 animals
treated
Prostration
Very rare
(<1 animal / 10000 animals treated)
Anaphylactic type reaction
1
of maximum 2x3.2 cm persisting for at least 8 days
Up to 1.8 °C for 2 hours on days 1 or 2 after vaccination.
For a view hours after vaccination.
Appropriate symptomatic treatment recommended.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or the national competent authority via the
national reporting system. See the package leaflet for respective contact details.

No information is available on the efficacy of the vaccine in animals with maternally
derived antibodies. However, these antibodies are usually not present in piglets at the age
of vaccination.
Vaccinate healthy animals only.

Special precautions for safe use in the target species:
Not applicable.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.

No information is available on the safety and efficacy of this vaccine when used with any
other veterinary medicinal product. A decision to use this vaccine before or after any other
veterinary medicinal product therefore needs to be made on a case by case basis.

Store and transport refrigerated (2 C – 8 C).
Do not freeze.
Protect from light.

Zero days.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.